Fibroids are common, benign and highly variable
Uterine fibroids, also called leiomyomas or myomas, are benign growths arising from uterine smooth muscle. They can be within the cavity, in the uterine wall, on the outer surface or attached by a stalk. Size, number and location vary widely, and a person may have one small incidental fibroid or multiple growths that alter the uterine cavity. [1]
Most fibroids are not cancer, and having fibroids does not mean a uterine cancer will develop. [3] The clinically important question is whether a fibroid plausibly contributes to heavy bleeding, pain, bulk symptoms, anemia or reproductive difficulty. An incidental fibroid without symptoms may need observation rather than intervention.
- Submucosal fibroids project toward the uterine cavity.
- Intramural fibroids sit within the uterine wall.
- Subserosal fibroids project toward the outer surface.
- Location often matters more than diameter alone.
Symptoms should drive the first decision
Fibroids can cause longer or heavier periods, bleeding between periods, cramps, pelvic pressure, urinary frequency, constipation, abdominal enlargement, back pain or pain with sex. Heavy blood loss can cause anemia. ACOG recommends considering treatment when symptoms disrupt activities, cause anemia, create significant pain or pressure, or when reproductive concerns are plausibly related. [1]
Symptoms overlap with adenomyosis, endometriosis, pregnancy-related conditions and endometrial pathology. Evaluation should include the bleeding pattern, pain timing, pressure symptoms, pregnancy goals, medications, anemia symptoms and relevant examination. Rapid growth alone does not establish cancer, but diagnostic uncertainty or postmenopausal growth warrants appropriate clinical review.
- Measure quality-of-life impact, not bleeding volume alone.
- Check a full blood count when bleeding is heavy. [2]
- Investigate bleeding between periods appropriately.
- Document bulk, bladder and bowel symptoms.
Imaging should answer a management question
Pelvic ultrasound is the usual first imaging test. It can document uterine size and the number, dimensions and locations of fibroids. Hysteroscopy or saline-infusion sonography may better define an intracavity lesion when heavy bleeding or fertility decisions depend on cavity shape. MRI can provide detailed mapping when ultrasound is inconclusive or before selected procedures. [1]
NICE recommends ultrasound before uterine artery embolization or myomectomy and considering MRI when more information about position, size, number or vascularity is needed. [2] Repeating scans without a decision question can create anxiety without improving care. Imaging intervals should be tied to symptoms, uncertainty, treatment planning or a meaningful clinical change.
- Ask whether the cavity is distorted.
- Link each reported fibroid to likely symptoms cautiously.
- Use the same measurement approach for follow-up where possible.
- Avoid equating imaging burden with symptom burden.
Treatment choices preserve different things
Medication can target bleeding or pain without removing fibroids. Options include tranexamic acid, nonsteroidal anti-inflammatory drugs, selected hormonal contraception, a levonorgestrel-releasing intrauterine device when the cavity is suitable, and gonadotropin-releasing hormone agonist or antagonist regimens for selected patients. Effects, contraindications and duration limits differ. [1]
Procedures include hysteroscopic, laparoscopic or open myomectomy; uterine artery embolization; radiofrequency ablation; focused ultrasound in selected settings; and hysterectomy. Hysterectomy is definitive but ends the ability to carry a pregnancy. Myomectomy preserves the uterus but new fibroids can develop. Evidence for pregnancy after embolization or ablation is less certain, so future pregnancy plans matter before consent.
- Bleeding control is different from shrinking a fibroid.
- Uterus-preserving is not always fertility-proven.
- Recovery time and reintervention risk belong in consent.
- Choice should reflect symptoms, anatomy and personal priorities.
Fertility decisions require precise anatomy and wider assessment
Fibroids may contribute to infertility or miscarriage, especially when they distort the uterine cavity, but other fertility factors are more common. ACOG advises evaluating other causes before attributing infertility to fibroids. [1] Age, ovulation, tubal status, semen factors, ovarian reserve when indicated and prior pregnancy history should inform the plan.
Removing a cavity-distorting fibroid may be considered when evidence and circumstances support it. For other fibroid locations, benefits are less predictable and must be weighed against surgical delay, adhesions, uterine scarring and obstetric implications. No scan can promise that treatment will produce a pregnancy. Reproductive and surgical specialists should align the intervention with the actual fertility pathway.
- Map relationship to the endometrial cavity.
- Complete an appropriate fertility evaluation.
- Discuss surgical approach and future birth planning.
- Avoid treating every fibroid found during infertility care.
Equity is a clinical quality issue
Fibroids occur more often, at younger ages and with greater symptom burden among Black women. ACOG notes that racism and social inequities may contribute to these differences. [1] NIH reviews also identify major racial differences in detected prevalence by the end of reproductive life. [4] These patterns should prompt better access and research, not biological stereotyping.
Quality care means timely evaluation of heavy bleeding, anemia and pain; discussion of the full range of options; preservation of fertility preferences; and avoidance of default hysterectomy when less invasive options are suitable. Outcome reporting should include symptom relief, complications, reintervention, reproductive outcomes and patient-reported experience across populations.
- Audit time from symptoms to diagnosis.
- Compare treatment access and outcomes by population.
- Offer anemia assessment and treatment promptly.
- Document shared decision making, not procedure alone.
What the evidence cannot yet answer
- Prevalence estimates vary because ultrasound detects fibroids that may never cause symptoms.
- Comparative studies of procedures differ in anatomy, age, symptom severity and reproductive goals.
- Pregnancy evidence after uterine artery embolization and radiofrequency ablation remains less established than symptom outcomes.
- Observed racial differences reflect intertwined biological, environmental, care-access and structural factors.
Questions worth taking into care
- Which fibroid is most likely to explain my symptom, and why?
- Do I have anemia or iron deficiency that needs treatment now?
- Would additional imaging change the decision?
- How does each option affect pregnancy, recovery and reintervention?
- Is observation safe, and what change should trigger review?
Source record
Evidence used in this review
Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.
- [1]Uterine Fibroids
American College of Obstetricians and Gynecologists · 2025
- [2]Heavy Menstrual Bleeding: Assessment and Management
National Institute for Health and Care Excellence · 2021
- [3]Uterine Fibroids
US Office on Women's Health · 2024
- [4]Uterine Fibroids and NIH Women's Health Research
National Institutes of Health · 2025
- [5]Abnormal Uterine Bleeding
American College of Obstetricians and Gynecologists · 2021
- [6]Uterine Fibroids
New England Journal of Medicine · 2025
This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.